Search bioRxiv⌕ Search

bioRxiv · 10.1101/2023.12.18.572068

Chemotherapy synergizes with cancer vaccines and expands stem-like TCF1+CD8+ T cells

Abstract

Therapeutic cancer vaccines, whether based on neoantigens or shared antigens, will likely be given in the clinic together with the standard of care, which often comprises immune checkpoint blockade therapy and chemotherapy. It remains unclear, however, whether vaccines effectively synergize with chemotherapy. Here, we tested the combination of a heterologous prime-boost viral vector vaccine with chemotherapy (CarboTaxol) and anti-PD- 1. We show that this triple combination improves tumor control and survival in different murine tumor models. CarboTaxol, and also cyclophosphamide, acted as an immune adjuvant for the vaccines, enhancing tumor-specific CD8+ T-cell responses, irrespective of the presence of a tumor. These chemotherapies expanded stem-like T cell factor 1 (TCF1)+CD8+ T cells. Inhibition of the transcriptional activity of TCF1/{beta}-catenin with a small molecule inhibitor abolished the immune adjuvant effect of CarboTaxol. This study sheds light on the new immunomodulatory roles of chemotherapies and holds promises for clinical testing of this combination strategy. HighlightsO_LIThe combination of CarboTaxol with viral vector cancer vaccines and anti-PD-1 promotes better tumor control, tumor clearance, and survival C_LIO_LICarboTaxol increases TCF1 expression in CD8+ T cells and expands stem-like TCF1+CD8+ T cells C_LIO_LICarboTaxol acts as an adjuvant for cancer vaccines irrespective of the presence of a tumor and this effect is mediated by TCF1/{beta}-catenin activity C_LI

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Noblecourt, L., Wicki, A., Pereira-Almeida, V., McAuliffe, J., Steffke, E., Panetti, S., Ramirez-Valdez, R. A., Chandrasekar, V., Jainarayanan, A., Hill, A. V., Van den Eynde, B. J., Leung, C. S. K.. 2023-12-18. Chemotherapy synergizes with cancer vaccines and expands stem-like TCF1+CD8+ T cells. https://doi.org/10.1101/2023.12.18.572068

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies

Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.

immunology↗

Development of lentiviral vectors specifically targeting CD4+ cells

Because of their central role in immunity, CD4+ T cells are a key target for genetic modification in many therapeutic applications, and lentiviral vectors with a VSV-G envelope are often used for this engineering. However, due to their broad tropism, these vectors are inadequate for cell-targeted in vivo gene delivery. Here, we explored using HIV-1 Env, which has a natural tropism towards these cells, as an alternative. We describe a three-plasmid vector production system to incorporate a panel of CCR5- or CXCR4-tropic Envs. These Env proteins are expressed from pCAG, a plasmid with reduced HIV-1 elements. We identify HIV-1 Env-incorporating vectors that can be produced with sufficient titres to specifically transduce primary CD4+ T cells in the context of in vitro mixed populations of peripheral blood mononuclear cells. We show efficient and specific transduction of HIV-1 Env vectors delivering an anti-CD19 chimeric antigen receptor (CAR). We demonstrate functional activity of the generated CD4+ CAR T cells, leading to the targeted killing of B cells in those mixed cell populations. Our methodology enables the production of HIV-1 Env-incorporating lentiviral vectors with defined CD4 targeted delivery, opening avenues for direct in vivo CAR T cell generation.

immunology↗

A Senescence-Like State is associated with the Immunosuppressive Phenotype of Tumor-Infiltrating Regulatory T Cells

Regulatory T (Treg) cells are essential mediators of immune suppression within the tumor microenvironment (TME) and represent a major barrier to effective anti-tumor immunity and to therapeutic efficacy of immune checkpoint inhibitors (ICIs). Cellular senescence is traditionally characterized by stable cell-cycle arrest accompanied by distinct molecular and functional changes, yet whether tumor-infiltrating (TI) Treg cells acquire senescence-associated features and how these features influence their immunosuppressive activity remain poorly understood. Here, we demonstrate that TI-Treg cells exhibit both apoptosis- and senescence-associated phenotype while retaining, and in some cases likely enhancing, their immunosuppressive capacity. Compared with peripheral Treg cells, some TI-Treg cells from solid cancers display elevated canonical senescence-associated markers, including p16 and p21, DNA damage response pathways, senescence-associated secretory phenotype (SASP) and anti-apoptotic BCL-2 family genes, as well as activation of secretion associated beta-galactosidase (SA-beta-Gal). Though physiological Treg senescence leads to diminished immune suppression, TI-Treg cells paradoxically maintain the expression of key immunosuppressive molecules. These findings identify a previously unrecognized senescence-like state in TI-Treg cells that is functionally distinct from the loss of fitness typically associated with senescence in other cell types or aging-associated Treg senescence. Our study establishes senescence-associated reprogramming as a defining feature of TI-Treg cells and highlights the senescence-like state of Treg cells as a potential therapeutic target for selectively disrupting tumor immune suppression while preserving systemic immune homeostasis.

immunology↗